Exercise as a pro-cognitive, pro-neurogenic and anti-inflammatory intervention in transgenic mouse models of Alzheimer's disease.

Exercise as a pro-cognitive, pro-neurogenic and anti-inflammatory intervention in transgenic mouse models of Alzheimer's disease. Ageing Res Rev. 2016 Mar 31; Authors: Ryan SM, Kelly ÁM Abstract It is now well established, at least in animal models, that exercise elicits potent pro-cognitive and pro-neurogenic effects. Alzheimer's disease (AD) is one of the leading causes of dementia and represents one of the greatest burdens on healthcare systems worldwide, with no effective treatment for the disease to date. Exercise presents a promising non-pharmacological option to potentially delay the onset of or slow down the progression of AD. Exercise interventions in mouse models of AD have been explored and have been found to reduce amyloid pathology and improve cognitive function. More recent studies have expanded the research question by investigating potential pro-neurogenic and anti-inflammatory effects of exercise In this review we summarise studies that have examined exercise-mediated effects on AD pathology, cognitive function, hippocampal neurogenesis and neuroinflammation in transgenic mouse models of AD. Furthermore, we attempt to identify the optimum exercise conditions required to elicit the greatest benefits, taking into account age and pathology of the model, as well as type and duration of exercise. PMID: 27039886 [PubMed - as supplied by publisher]
Source: Ageing Research Reviews - Category: Genetics & Stem Cells Authors: Tags: Ageing Res Rev Source Type: research

Related Links:

CONCLUSION: The DLG model can achieve higher accuracy and sensitivity when applied to progression of AD. More importantly, we discovered several novel genetic biomarkers of AD progression, including rs6311 and rs6313 in HTR2A, rs1354269 in NAV2, and rs690705 in RFC3. The roles of these novel loci in AD should be explored in future research.PMID:34336000 | PMC:PMC8298161 | DOI:10.1155/2021/3359103
Source: Behavioural Neurology - Category: Neurology Authors: Source Type: research
Expert Rev Neurother. 2021 Aug 2. doi: 10.1080/14737175.2021.1960823. Online ahead of print.ABSTRACTIntroduction: Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most common cause of dementia. It has a complex pathophysiology that is not yet completely understood, where multiple central, systemic and environmental factors play a key role in disease progression. Understanding the multifactorial nature of AD is paramount to formulate new therapies.Areas covered: The authors reviewed the role of the amyloid-β-binding, antioxidant and immunomodulatory properties of albumin in AD and the use of ther...
Source: Expert Review of Neurotherapeutics - Category: Neurology Authors: Source Type: research
Conclusion: This study provides preliminary evidence highlighting that 16:3 cholesteryl ester were useful for AD disease monitoring while ganglioside GM3 (d18:1/9z-18:1) and neuromedin B discriminated aMCI from HC, which can probably be applied in clinic for early predicting of AD.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
AbstractThe decline in autobiographical memory function in people with Alzheimer ’s dementia (AD) has been argued to cause a loss of self-identity. Prior research suggests that people perceive changes in moral traits and loss of memories with a “social-moral core” as most impactful to the maintenance of identity. However, such research has so far asked people to rate from a third-person perspective, considering the extent to which hypothetical others maintain their identity in the face of various impairments. In the current study, we examined the impact of perspective, comparing first- and third-person pe...
Source: Neuroethics - Category: Medical Ethics Source Type: research
This study aimed to determine the association between: (i) cognitive decline and bone loss; and (ii) clinically significant cognitive decline on Mini Mental State Examination (MMSE) over the first 5 years and subsequent fracture risk over the following 10 years. A total of 1741 women and 620 men aged ≥65 years from the population-based Canadian Multicentre Osteoporosis Study were followed from 1997 to 2013. Over 95% of participants had normal cognition at baseline. After multivariable adjustment, cognitive decline was associated with bone loss in women but not men. Approximately 13% of participants ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ALZHEIMER'S disease is the most common cause of dementia in the UK, but there's currently no cure. Spotting the condition early can help a person understand their diagnosis. A recent study revealed early signs in people's driving.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Am J Pathol. 2021 Jul 28:S0002-9440(21)00341-2. doi: 10.1016/j.ajpath.2021.07.004. Online ahead of print.ABSTRACTAlzheimer's disease is the most common cause of dementia. Biological definitions of AD are limited to the cerebral burden of amyloid β plaques, neurofibrillary pathology and neurodegeneration. However, current evidence suggests various features of small vessel disease (SVD) are part and parcel of and covertly modify both sporadic and familial AD. Neuroimaging studies suggest white matter hyperintensities (WMH) explained by vascular mechanisms occur frequently in the AD spectrum. Recent advances have further...
Source: The American Journal of Pathology - Category: Pathology Authors: Source Type: research
Drug Discov Today. 2021 Jul 28:S1359-6446(21)00325-1. doi: 10.1016/j.drudis.2021.07.020. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is an irreversible dementia state with characteristic clinical manifestations, including declining cognitive skills and loss of memory, which particularly affects the older population. Despite significant efforts in the field of nano-based drug delivery, there have been few successes achieved in the design of a rational drug therapy. Nanoemulsions (NEs) have potential for the delivery of AD therapeutics owing to their capability for brain drug delivery. Still, there is a long way t...
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research
Am J Pathol. 2021 Jul 28:S0002-9440(21)00341-2. doi: 10.1016/j.ajpath.2021.07.004. Online ahead of print.ABSTRACTAlzheimer's disease is the most common cause of dementia. Biological definitions of AD are limited to the cerebral burden of amyloid β plaques, neurofibrillary pathology and neurodegeneration. However, current evidence suggests various features of small vessel disease (SVD) are part and parcel of and covertly modify both sporadic and familial AD. Neuroimaging studies suggest white matter hyperintensities (WMH) explained by vascular mechanisms occur frequently in the AD spectrum. Recent advances have further...
Source: Am J Pathol - Category: Pathology Authors: Source Type: research
Drug Discov Today. 2021 Jul 28:S1359-6446(21)00325-1. doi: 10.1016/j.drudis.2021.07.020. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is an irreversible dementia state with characteristic clinical manifestations, including declining cognitive skills and loss of memory, which particularly affects the older population. Despite significant efforts in the field of nano-based drug delivery, there have been few successes achieved in the design of a rational drug therapy. Nanoemulsions (NEs) have potential for the delivery of AD therapeutics owing to their capability for brain drug delivery. Still, there is a long way t...
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Alzheimer's | Dementia | Genetics | Neurology | Pathology | Sports Medicine | Study